Phase 3 topline data from azetukalner FOS epilepsy program planned for H2 2025 in support of NDA filing and potential commercial launch– First ...

Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label extension in Q1 2025Phase 1 clinical trial to evaluate ...

A higher comorbidity burden was linked to an increased rate of adverse events as well as early discontinuation among patients ...

Phase 3 topline data from azetukalner FOS epilepsy program planned for H2 2025 in support of NDA filing and potential commercial launch - First of three planned Phase 3 azetukalner MDD studies underwa ...

A global elderly and aging population has significant impacts, not only in terms of individual health risk but in terms of ...

ACCESS and ACCESS II studies fully enrolled; topline data from both studies anticipated by year-end 2025Oral small ...

The stress axis that has been most extensively studied in relation to stress is unquestionably the hypothalamic pituitary ...

RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and OS Therapies Inc. (NYSE American:OSTX) on the RedChip Small Stocks, Big Money™ show, a sponsored ...

Arcutis is proud to support Dr. Candrice Heath of the Heath Health Foundation for Education and Research by hosting two experiential learning sessions at its booth focused on Culturally Conscious ...

It is rated on a 2026 PE ratio of 10 even though the integration of bolt-on acquisitions will help drive future growth ...

Linvoseltamab is an investigational BCMAxCD3 bispecific antibody designed to bridge B-cell maturation antigen (BCMA) on MM cells with CD3-expressing T cells to facilitate T-cell activation and ...

Candel Therapeutics (NASDAQ:CADL – Get Free Report) had its price target upped by stock analysts at Canaccord Genuity Group from $20.00 to $25.00 in a report issued on Wednesday,Benzinga reports. The ...